Tenaya Therapeutics (TNYA) Operating Income (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Operating Income of -$20.1 million for Q1 2026, up 27.14% year-over-year from -$15.8 million in Q1 2025, and up 3.42% quarter-over-quarter from -$20.8 million in Q4 2025.
Tenaya Therapeutics (TNYA) Operating Income (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$20.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 27.14% year-over-year to -$20.1 million; the TTM figure through Mar 2026 stood at -$85.9 million (up 21.75% YoY), while the FY2025 annual figure was -$93.3 million, up 19.51% from the prior year.
- Operating Income for Q1 2026 stood at -$20.1 million, up from -$20.8 million in the prior quarter.
- The five-year high for Operating Income was -$20.1 million in Q1 2026, with the low at -$35.1 million in Q2 2023.
- The 5-year median for Operating Income is -$30.8 million (2024), against an average of -$28.6 million.
- The sharpest annual moves came in 2022 and 2026: Operating Income sank 137.73% in 2022, then increased 27.14% in 2026.
- Tenaya Therapeutics' Operating Income stood at -$34.6 million in 2022, then climbed by 8.98% to -$31.4 million in 2023, then climbed by 21.61% to -$24.7 million in 2024, then increased by 15.73% to -$20.8 million in 2025, then advanced by 3.42% to -$20.1 million in 2026.
- Business Quant data shows TNYA's Operating Income at -$20.1 million in Q1 2026, -$20.8 million in Q4 2025, and -$20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | -44.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.09 Mn |
| Mar 31, 2026 | -20.07 Mn |
| Dec 31, 2025 | -20.78 Mn |
| Sep 30, 2025 | -20.94 Mn |
| Jun 30, 2025 | -24.08 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | -24.65 Mn |
| Sep 30, 2024 | -26.71 Mn |
| Jun 30, 2024 | -30.82 Mn |
| Mar 31, 2024 | -33.76 Mn |
| Dec 31, 2023 | -31.45 Mn |
| Sep 30, 2023 | -30.92 Mn |
| Jun 30, 2023 | -35.10 Mn |
| Mar 31, 2023 | -33.72 Mn |
| Dec 31, 2022 | -34.55 Mn |
| Sep 30, 2022 | -31.30 Mn |
| Jun 30, 2022 | -28.62 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | -26.16 Mn |
| Sep 30, 2021 | -18.30 Mn |